A nanobody discovery CRO plans and performs the laboratory work needed to identify and characterize single-domain antibody binders against a target. For veterinary medicine projects, the workflow should reflect the intended species, sample type, and use case—such as a diagnostic assay, research reagent, or therapeutic lead. Typical work can include target review, library or immunization strategy, binder screening, sequence identification, and initial characterization. Before requesting a proposal, define the target, intended application, required evidence, and expected deliverables.
This guide is for veterinary diagnostics companies, animal-health biotechnology teams, research groups, and other B2B buyers considering a custom nanobody project. It is also useful if you are comparing CRO proposals and need to understand what a discovery package should include. The details below are intended to help you prepare a practical brief, not to prescribe a single workflow for every target. Discovery design depends on target properties, project constraints, and the evidence needed for your next decision.
Nanobodies are antibody-derived binding domains commonly associated with camelid heavy-chain antibodies. A VHH domain is often approximately 12–15 kDa and roughly 110–130 amino acids long; these are general reference ranges, not acceptance specifications for an individual candidate. Compared with a conventional IgG antibody, a VHH is a smaller binding format, but that fact alone does not establish its suitability, affinity, stability, or performance in a veterinary assay.
A discovery CRO helps turn a target and project objective into candidate molecules supported by experimental evidence. Depending on the agreed scope, work may cover antigen assessment, library selection or animal immunization, display-based screening, sequence analysis, recombinant expression, and binding validation. Some projects stop at sequence-identified hits, while others include additional specificity, functional, or developability assessments. Buyers should confirm exactly where the contracted work ends.
Start by describing the target, its biological context, and what the binder must do. For example, a reagent intended to detect a pathogen antigen in a veterinary diagnostic assay has different requirements from a binder intended to block a receptor in a research model. Share available antigen information, including construct boundaries, species of origin, tags, expression system, and known structural or post-translational features. If the target is membrane-bound or difficult to purify, discuss how its relevant form will be represented during discovery.
Common options include immunization-based discovery and selection from an existing or synthetic display library. Immunization may be considered when a suitable animal-immunization program is available and the project can accommodate its requirements; library-based approaches may offer a different route when immunization is unsuitable or project constraints favor in vitro selection. Neither strategy guarantees a useful binder, and feasibility depends on the target and screening design. Ask the CRO to explain why its proposed route fits your antigen and intended application.
Screening commonly uses a display and selection method followed by assays to distinguish target-reactive candidates from background binders. The proposal should identify the antigen presentation method, negative or counter-selection controls, and how sequence diversity will be assessed. For veterinary work, consider counter-screening against related proteins or species variants when cross-reactivity could affect the product. A positive signal in one screening assay is a starting point, not proof of performance in a finished diagnostic or therapeutic context.
Following sequence identification, selected candidates may be produced recombinantly for further evaluation. Depending on scope, characterization can include identity confirmation, expression observations, binding assays, specificity testing, or functional assays. Ask which methods will be used, what controls are included, and whether raw data and analysis files will be supplied. An illustrative buyer-defined criterion might be a minimum purity target of 90% for a research-grade preparation, but this is not a universal standard and should be agreed in light of the downstream use.
For more information, please visit NBbiolab.
A useful handoff package may include candidate sequences, experimental methods, assay results, sample identifiers, and recommendations for follow-up. Confirm whether physical materials—such as plasmids, expressed protein, or cell stocks—are included, and specify format, quantity, and shipping conditions in the contract. Discovery does not automatically include scale-up, formulation, regulatory strategy, or commercial manufacturing. Treat these as separate work packages unless they are explicitly included.
For veterinary diagnostics, prioritize the target form and assay conditions that best represent the intended sample and test format. If the assay will use serum, whole blood, fecal material, milk, or another matrix, discuss matrix-related interference and how later validation will be handled. A discovery-stage binding result does not establish diagnostic sensitivity or specificity in clinical samples. Those performance claims require appropriately designed validation with relevant specimens and controls.
For veterinary research reagents, consider whether the binder must recognize a specific animal species, a conserved epitope, or a particular protein variant. For therapeutic lead discovery, the brief may need additional functional and safety-related questions, as well as a longer development pathway than a research-use reagent. Include intended species, route or model context where relevant, and the decision the candidate is expected to support. These details help the CRO distinguish a screening hit from a lead suitable for further development.
Ask the provider to map each project stage to a decision and a deliverable. The proposal should explain how it will address target quality, assay controls, candidate prioritization, and failure or re-screening scenarios. Look for clear distinctions between what is guaranteed as a contracted activity and what is only a possible outcome. Be cautious of any proposal that promises a particular affinity or functional result before the target and assay have been assessed.
Confirm who owns the resulting sequences, data, and project-specific materials, and whether any license or use restrictions apply. Ask how deviations, sample issues, and milestone reviews will be communicated. You should also establish which records are delivered, how data are organized, and how long materials can be retained. These points reduce ambiguity when the project moves from discovery to internal development or another supplier.
Nanobody discovery pricing and lead time vary with target complexity, discovery route, number of screening rounds, characterization depth, and material requirements. Compare proposals by work package rather than headline price, and check whether antigen production, expression, repeat experiments, shipping, and downstream testing are included. Request a project-specific schedule with milestone assumptions instead of relying on a generic turnaround estimate. A low initial quote may not cover the evidence or materials your team needs for its next decision.
| Evaluation area | Questions to ask the CRO |
|---|---|
| Target feasibility | What target information or antigen material is needed, and what risks do you see? |
| Screening quality | Which controls, counter-selections, and confirmation assays are included? |
| Deliverables | Will we receive sequences, data, methods, and physical materials? |
| Commercial terms | How are ownership, permitted use, optional work, and schedule changes handled? |
At NBbiolab, we work with B2B buyers to clarify project objectives and evaluate a suitable nanobody discovery scope. To help us assess feasibility, share the target identity, species context, intended application, available antigen information, and any required controls or downstream assays. We can then discuss the proposed workflow, expected deliverables, project assumptions, and quotation on a project-specific basis. A clear brief at the outset makes it easier to compare options and avoid paying for work that does not support your next decision.
A nanobody discovery CRO can provide a structured route from target definition to sequence-identified and characterized candidates, but the value of the project depends on how well its workflow matches your veterinary application. Before selecting a vendor, align on the discovery strategy, controls, characterization depth, deliverables, ownership, and commercial scope. Do not treat an early binding signal as proof of clinical, diagnostic, or therapeutic performance. Prepare a one-page project brief with your target, intended use, species requirements, available materials, and decision criteria, then request a written proposal from NBbiolab or other qualified providers for comparison.
Contact us to discuss your requirements of Nanobody Discovery CRO. Our experienced sales team can help you identify the options that best suit your needs.